ISRCTN31630783已完成未知
Efficacy and tolerability of Menthacarin® in patients (= 18 years old) suffering from symptoms of irritable bowel syndrome (IBS)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 226
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 years and over
- •2. Provision of written informed consent in accordance with the legal requirements
- •3. Willing and able to comply with all study procedures
- •4. Diagnosis of irritable bowel syndrome (IBS) based on the following criteria:
- •4.1. Presence of IBS symptoms (e.g. abdominal pain, flatulence) for > 3 months
- •4.2. IBS symptoms are ascribed by both patient and physician to the gut and usually accompanied by altered bowel habits
- •4.3. The IBS complaints are the reason, why the subject consulted the physician
- •4.4. No changes characteristic of other diseases are present that are likely to be the cause of the symptoms
- •5. Numeric Rating Scale (NRS) assessing severity of pain > 3 points at visit 1 and visit 2, respectively
- •6. Any reduction in numeric pain rating scale (NRS) assessing severity of pain at visit 2 not greater than one point in comparison to visit 1
- •7. IBS-Severity Scoring System (IBS-SSS) > 80 points at visit 1 and 2, respectively
- •8. Any reduction in IBS-SSS at visit 2 in comparison to visit 1 is < 25 points
排除标准
- •1. History of chronic or evident acute liver, heart, respiratory tract, pulmonary, muscular (e.g. M. gravis) or renal disease
- •2. History or suspected glaucoma (angel-closure glaucoma)
- •3. Subjects with a history of urinary retention by mechanical narrowing of the urinary tract (e.g. enlarged prostate)
- •4. History of renal or hepatic dysfunction (serum creatinine, serum AST or ALT at least 3 folds above the upper limit of normal range or alkaline phosphatase > 2 fold above the upper limit of normal) within the last 12 months prior to inclusion into the study
- •5. Subject with known or suspected gall bladder inflammation (cholangitis), is suffering from gall stone, occlusion of the bile ducts or other diseases of the gall bladder, sphincter Oddi dysfunction, or abdominal adhesions
- •6. History or suspected pancreatitis, ileus, or any gastrointestinal bleeding
- •7. Female subject suffering from endometriosis
- •8. Subject is immune-compromised (e.g. AIDS, lymphoma, long-term corticosteroid treatment)
- •9. Subject with malignant tumours or undergoing chemotherapy or radiation therapy
- •10. Evidence of structural abnormality of the gastrointestinal tract or diseases/conditions that affect bowel transit (e.g. mega-colon)
- •11. Subject is suffering from gastro-oesophageal reflux disease (GERD) or reduced production of gastric acid (achlorhydria)
- •12. Evident or suspected other causes for diarrhoea such microscopic colitis, celiac disease
- •13. Subject is currently experiencing nausea, fever > 38.5 °C (measured using an infrared ear thermometer), vomiting, or bloody diarrhoea
- •14. Subject with history of a gastrointestinal surgery (except appendectomy conducted before one year or longer)
- •15. Subject with clinically significant abnormal results of laboratory tests at the time point of visit 1 (including haematology tests, serum chemistry tests, thyroid function tests)
- •16. Subject is 50 years or older who has been diagnosed with IBS and has not received a colonoscopy in the last 6 months prior to inclusion into the study
- •17. Subject with history of positive test of blood in stool within the last 6 months prior to inclusion into the study
- •18. Subject with history of clinically relevant increase in stool calprotectin within the last 6 months prior to inclusion into the study
- •19. Subject using or has used antipsychotic, antidepressive or anticholinergic medication within one month prior to inclusion into the study
- •20. Previous (within the last 14 days) or concomitant use of analgesics, prokinetics, sedatives, laxatives, anti-diarrhoeal agents, steroidal agents, antacids, proton-pump inhibitors, anti-coagulants, antibiotics or probiotics
- •21. Known or suspected hypersensitivity to the investigational drug or to one of its excipients or to peppermint, menthol, caraway, or to umbelliferous plants or to the rescue medication (BUSCOPAN® PLUS) offered in the study or one of its excipients
- •22. Previous (within the last 30 days) or current use of medications for the treatment of IBS (including herbal preparations)
- •23. Women with positive pregnancy test at visit 1
- •24. Pregnant or breast-feeding women
研究者
相似试验
进行中（未招募）
1 期
A clinical study to determine how effective Menthacarin is for patients with Irritable Bowel Syndrome, and to determine the possible side effects of the product.EUCTR2014-004702-14-DEDr. Willmar Schwabe GmbH & Co. KG200
进行中（未招募）
1 期
Menthacarin® in the treatment of functional gastrointestinal disordersCTIS2022-501800-92-00Dr. Willmar Schwabe GmbH & Co. KG120
招募中
2 期
Evaluaion of tolerability and efficacy of Melatrance lightening cream for the treatment of melasmaChloasmaIRCT20190210042676N25Knowledge-based company of Janus20
已完成
3 期
se of memantin in treatment of adult with attention deficit hyperactivity disorderAdult ADHD (Attention-deficit hyperactivity disorder ).Disturbance of activity and attentionIRCT2016053028182N1Kurdistan University of Medical science40
已完成
2 期
Memantine effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N2Vice chancellor for research, Mazandaran University of Medical Sciences50